Accesswire
18 May 2026, 06:40 UTC · 3d ago
Source · https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/spago-nanomedical-presents-tumoradr-clinical-data-at-the-internationa-1167686
Read source
Search tags
Story key points
3 claims · impact-rated
The independent Data Monitoring Committee (DMC) assessed the observed tumor uptake as proof-of-concept for Tumorad as a potential new treatment approach for advanced cancer. — An official proof-of-concept designation from an independent safety/monitoring body is a major clinical milestone for an early-stage biotech, significantly derisking the program and validating the mechanism of action.
+0.80SPECT/CT imaging demonstrated visible tumor uptake of ¹⁷⁷Lu-SN201 in two patients with different severe head and neck cancers. — Visible tumor uptake in human patients confirms target engagement and supports the drug's hypothesized mechanism of action, though it is early-stage data from just two individuals.
+0.60The Tumorad-01 study is progressing towards defining the recommended phase II dose (RP2D) and will shift focus to generating efficacy data in Phase II. — Transitioning from safety/dosimetry to defining the Phase II dose and generating efficacy data advances the clinical timeline and signals tolerability in earlier cohorts, bringing the asset closer to commercial relevance.
Impact vectors
3 dimensions · 9 clusters
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
Ticker attribution
Model heads
The company presented positive clinical data showing proof-of-concept tumor uptake for its drug candidate Tumorad.
No ticker relationship head found.
